|
Nov 13
|
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
|
|
Nov 9
|
Top 20 Drug Companies in the US by Revenue
|
|
Nov 9
|
The Viatris Inc (VTRS) Company: A Short SWOT Analysis
|
|
Nov 8
|
Viatris Inc. (NASDAQ:VTRS) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip
|
|
Nov 8
|
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
|
|
Nov 7
|
Viatris (VTRS) Beats Q3 Earnings Estimates
|
|
Nov 7
|
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
|
|
Nov 6
|
Should You Buy Viatris (VTRS) Ahead of Earnings?
|
|
Nov 6
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Nov 6
|
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
|
|
Nov 5
|
Is Viatris (VTRS) a Smart Long-Term Pick?
|
|
Sep 12
|
Viatris Named to TIME's World’s Best Companies 2023 List
|
|
Sep 9
|
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
|
|
Sep 6
|
Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A Comprehensive Guide
|
|
Sep 6
|
Unraveling the Future of Viatris Inc (VTRS): A Deep Dive into Key Metrics
|
|
Sep 6
|
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
|
|
Aug 11
|
2 Beaten-Down Dividend Stocks to Buy
|
|
Aug 11
|
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
|
|
Aug 10
|
Viatris Has Been Bearish for One Reason — But Is Still an Intriguing Value Play
|